The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, AVEO, AMRN and CVS – iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Mar 19, 2019 6:00 AM ET

Subject to Terms of Use.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, AVEO, AMRN and CVS

Legal Newswire iCrowdNewswire - Mar 19, 2019

NEW YORK,  — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

Maxar Technologies Inc. (NYSE: MAXR)
Class Period: March 29, 2018 to January 7, 2019
Lead Plaintiff Deadline: March 15, 2019

The lawsuit alleges that throughout the class period, Maxar Technologies Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

Get additional information about the MAXR lawsuit: http://www.kleinstocklaw.com/pslra-1/maxar-technologies-inc-loss-submission-form?wire=3

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 to January 31, 2019
Lead Plaintiff Deadline: April 26, 2019

According to the complaint, AVEO Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

Get additional information about the AVEO lawsuit: http://www.kleinstocklaw.com/pslra-1/aveo-pharmaceuticals-inc-loss-submission-form?wire=3

Amarin Corporation (NASDAQGM: AMRN)
Class Period: September 24, 2018 to November 9, 2018
Lead Plaintiff Deadline: April 23, 2019

The lawsuit alleges that throughout the class period, Amarin Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

Get additional information about the AMRN lawsuit: http://www.kleinstocklaw.com/pslra-1/amarin-corporation-loss-submission-form?wire=3

CVS Health Corporation (NYSE: CVS)
Class Period: May 21, 2015 to February 20, 2019
Lead Plaintiff Deadline: April 26, 2019

The lawsuit alleges CVS Health Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) CVS Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (ii) as a result, CVS Health’s public statements were materially false and misleading at all relevant times.

Get additional information about the CVS lawsuit: http://www.kleinstocklaw.com/pslra-1/cvs-health-corporation-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Keywords:  
Tags: Wire, Legal Newswire, United States, English
View Related News >